Targeting cell-state plasticity driven by FOXM1/CEBPB axis disrupts developmental heterogeneity and therapeutic...

Phenotypic plasticity generates heterogeneous cellular states that span the developmental hierarchy and drive therapeutic resistance in hepatocellular carcinoma (HCC). However, the factors governing this developmental heterogeneity remain unclear, and therapeutic interventions are lacking.

Autoregulatory network analysis was performed on public datasets of bulk RNA sequencing and single-cell RNA sequencing data from patients with HCC, as well as on our hepatocyte differentiation model, to identify key transcriptional regulators governing the transition of cellular states during hepatic differentiation. In vitro and in vivo models were used to investigate molecular mechanisms and evaluate therapeutic potential.

We demonstrate dynamic cell-state transitions with chaotic developmental trajectories in the malignant progression of HCC. High developmental diversity is closely linked to the activation of drug resistance genes and immune evasion, significantly affecting patient prognosis. We identify that the FOXM1/CEBPB axis at the apex controls developmental heterogeneity dynamics. FOXM1/CEBPB form a master decision toggle switch by mutually suppressing each other and competing for control over downstream state-specific networks. Inhibiting FOXM1 restores tumor developmental homogeneity, re-exposing tumor cells to immune surveillance. The likely mechanism is the activation of IFN-γ signaling and antigen presentation. A GalNAc-conjugated, chemically modified small-interfering RNA compound targeting hepatic FOXM1 was designed and showed strong potency and tolerability in therapeutic mouse models.

Tumor cell-state plasticity driven by the FOXM1/CEBPB axis induces developmental heterogeneity and therapeutic resistance in HCC. RNA interference-based therapies targeting hepatic FOXM1 showed strong potential for further clinical testing.

Tumor heterogeneity and therapeutic resistance remain major barriers in cancer treatment, largely driven by dynamic transitions across multiple cellular states. This study reveals that the FOXM1/CEBPB axis is a crucial regulator of these hierarchical cellular transitions and plays a key role in sustaining developmental heterogeneity and promoting resistance to therapies. By targeting this axis, we demonstrated the restoration of developmental homogeneity and significant disruption of therapeutic resistance in preclinical models. Furthermore, our findings highlight the strong efficacy of RNAi-based therapeutics directed at hepatic FOXM1, highlighting their promising potential as pioneering small nucleic acid drugs for cancer therapy.